References
Seledtsova GV, Shishkov AA, Kaschenko EA, Goncharov AG, Gazatova ND, Deledtsov VI. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits. Eur J Dermatol 2016; 26: 138–43.
Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Ostapenko V, Schijns V. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? Vaccine 2014; 32: 4015–24.
Singh M, Overwijk WW. Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother 2015; 64: 911–21.
Dervis E, Ayer M, Belli AA. Gul Barut S. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A 6-year follow-up. Eur J Dermatol 2016; 26: 133–7.
Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013; 27: 1471–80.
Dreno B, Jean-Decoster C, Georgescu V. Profile of patients with mild to moderate acne in Europe: a survey. Eur J Dermatol 2016; 26: 177–84.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Behle, V., Villani, AP., Cabete, J. et al. Residents’corner March-April 2016. Editorial: What’s new this month?. Eur J Dermatol 26, 214–215 (2016). https://doi.org/10.1684/ejd.2016.2800
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2016.2800